Literature DB >> 14627166

Inhibition of in vitro intracellular growth of Trypanosoma cruzi by dicationic compounds.

Edwin C Rowland1, Deborah Moore-Lai, John R Seed, Chad E Stephens, David W Boykin.   

Abstract

Dicationic compounds, which are derivatives of pentamidine, are being developed for use as antiprotozoal drugs. These compounds bind to the minor groove of DNA and are thought to inhibit DNA-dependent enzymes and thereby prevent cellular replication by protozoans. The objective of this study was to test the ability of a group of these compounds to inhibit the intracellular and extracellular reproduction of Trypanosoma cruzi in vitro. At present, there are few drugs in use capable of inhibiting the intracellular stages of this parasite, and therefore compounds with this ability would be of value. Cultures of mouse fibroblasts were infected and treated with doses of dicationic compounds, and the numbers of parasites released at the end of the 5- to 7-day growth cycle were determined. Five of the compounds tested were found to be effective at inhibiting T. cruzi growth at doses that were not toxic to the host cells. The compound found most effective (DB709) inhibited parasite release at the low concentration of 0.8 ng/ ml, justifying further study. These results suggest that dicationic compounds may have potential as chemotherapy against T. cruzi infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627166     DOI: 10.1645/GE-53R

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  2 in total

1.  High-content imaging for automated determination of host-cell infection rate by the intracellular parasite Trypanosoma cruzi.

Authors:  L L Nohara; C Lema; J O Bader; R J Aguilera; I C Almeida
Journal:  Parasitol Int       Date:  2010-08-03       Impact factor: 2.230

Review 2.  Chagas' disease: an update on immune mechanisms and therapeutic strategies.

Authors:  Silvia Beatriz Boscardin; Ana Claudia Troccoli Torrecilhas; Romina Manarin; Silvia Revelli; Elena Gonzalez Rey; Renata Rosito Tonelli; Ariel Mariano Silber
Journal:  J Cell Mol Med       Date:  2010-01-11       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.